Anti-egfr therapy

Show results for

Unknown (1231)
Transcriptomics (397)
Genomics (139)
Clinical (55)
Proteomics (31)
Other (5)
Metabolomics (2)
Genomic (1)
Methylation profiling (1)

Organisms

Homo sapiens (209)
Mus musculus (115)
Drosophila melanogaster (9)
Rattus norvegicus (8)
Sus scrofa (7)
Arabidopsis thaliana (6)
Bos taurus (5)
Danio rerio (5)
Saccharomyces cerevisiae (4)
Macaca mulatta (3)
Boehmeria nivea (2)
Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 (2)
Thermus thermophilus HB8 (2)
Brugia pahangi (2)
Zea mays (2)
Schizosaccharomyces pombe (2)
Campylobacter jejuni (2)
Oryza sativa Japonica Group (2)
Caenorhabditis elegans (2)
Gallus gallus (2)
gamma proteobacterium HTCC2207 (1)
Staphylococcus xylosus (1)
Larimichthys crocea (1)
Saccharum sp. (1)
Chenopodium amaranticolor (1)
Cucumis sativus var. sativus (1)
Vibrio cholerae O1 biovar El Tor str. N16961 (1)
Cryptomeria japonica (1)
Musa acuminata (1)
Synechococcus sp. WH 7803 (1)

Organisms

Homo sapiens (68)
Mus musculus (17)
mouse skin metagenome (3)

Repository

biostudies-arrayexpress (341)
ENA (109)
geo (78)
EGA (20)
pride (18)
iProX (3)
jPOST (2)
MassIVE (2)
MetaboLights (2)
dbGaP (1)

Tissue

Cell culture (7)
Lung (6)
Epithelial cell (5)
Kidney (3)
Colon (2)
Early embryonic cell (2)
Blood (1)
Macrophage (1)
Monocyte (1)

Disease

Colorectal Neoplasms (33)
Adenocarcinoma (2)
Carcinoma (2)
Colorectal cancer (2)
Colorectal cancer (2)
Rectal Neoplasms (2)
Non-small cell lung carcinoma (2)
GIP-dependent Cushing's syndrome (1)
HPV positive (1)
Glioblastoma (1)
Inoperable, untreated, wild type RAS (wt KRAS/wtNRAS), metastatic colorectal cancer (mCRC) (1)
Advanced colorectal tumors (1)
Blood magnesium decreased (1)
Colorectal cancer metastatic (1)
Patients with histologically confirmed metastatic colorectal cancer (1)
Malignant neoplasm of colon (1)
Histologically or cytologically confirmed UICC stage IV carcinoma of colon or rectum with metastasis (metastatic colorectal cancer) with need for treatment due to progression (1)
Malignant neoplasm of colon, unspecified (1)
Melanoma (1)
Metastatic colorectal cancer (1)
Neoplasm Metastasis (1)
Metastatic colorectal cancer (1)
Acute leukemia (1)
Breast cancer (1)
Colon cancer (1)
Disease free (1)
Lung carcinoma (1)
Lymphoma (1)
Urinary system benign neoplasm (1)

Technology Type

Mass Spectrometry (18)
Shotgun proteomics (14)
Mass spectrometry (2)
Bottom-up proteomics (2)
Illumina MiSeq (1)
Affinity purification coupled with mass spectrometry proteomics (1)
Data-dependent acquisition (1)
Data-independent acquisition (1)

Instrument Platform

Liquid Chromatography MS - negative - hilic (2)
Liquid Chromatography MS - positive - hilic (2)
Illumina MiSeq (1)
NextSeq 550 (1)
Illumina HiSeq 2000 (1)
Illumina HiSeq 4000 (1)
Orbitrap Fusion Lumos (1)
Q-Exactive Plus Orbitrap mass spectrometer (1)
MS Imaging - (1)

Publication Date

2012 (59)
2010 (52)
2015 (51)
2013 (44)
2014 (41)
2011 (37)
2016 (21)
2009 (18)
2024 (18)
2008 (16)
2026 (16)
2025 (14)
2021 (13)
2023 (9)
2020 (8)
2007 (7)
2018 (7)
2022 (6)
2019 (5)
2006 (1)
2005 (1)
2004 (1)
2003 (1)

CHEBI ID

CHEBI:38263 (2)
CHEBI:17822 (2)
CHEBI:17126 (2)
CHEBI:27570 (2)
CHEBI:28300 (2)
CHEBI:24898 (2)
CHEBI:28044 (2)
CHEBI:21557 (2)
CHEBI:29016 (2)
CHEBI:15891 (2)
CHEBI:6650 (2)
CHEBI:18237 (2)
CHEBI:16668 (2)
CHEBI:73024 (2)
CHEBI:17858 (2)
CHEBI:16027 (2)
CHEBI:16680 (2)
CHEBI:53210 (2)
CHEBI:32316 (1)
CHEBI:52289 (1)
CHEBI:79401 (1)
CHEBI:165053 (1)
CHEBI:94166 (1)
CHEBI:164874 (1)
CHEBI:164773 (1)
CHEBI:164635 (1)
CHEBI:164556 (1)
CHEBI:81980 (1)
CHEBI:81979 (1)
CHEBI:184111 (1)

Metabolite Name

Theronine (1)
Adenosylhomocysteine (1)
Tyr-Glu-Arg (1)
Trp-Cys-Arg (1)
Trietazine (1)
Simazine hydroxy (1)
(-)-perillyl alcohol (1)
N-acetyldihydrosphingosine (1)
Methyl gamma-linolenate (1)
Maackiaine (1)
Lstb (1)
Leu-Trp-Arg (1)
L-arachidonoylcarnitine (1)
Ile-Ser-Lys (1)
Dl-alpha-phenylglycine (1)
.delta.-dodecalactone (1)
D-cycloserine (1)
D-amygdalin (1)
Cis-4,10,13,16-docosatetraenoic acid (1)
Asp-Thr-Arg (1)
Arachidonoylglycine (1)
Androstane-3,17-diol, (3beta,5alpha,17beta)- (1)
Alpha-ionone (1)
Alpha,alpha'-trehalose 6-phosphate (1)
Acetylpodocarpic acid anhydride (1)
8,11-tridecadienoic acid, 13-(3-pentyl-2-oxiranyl)-, methyl ester, (8z,11z)- (1)
7-oxocholesterol (1)
6''-o-malonylglycitin (1)
6-ketoprostaglandin f1alpha (1)
6,3',4'-trimethoxyflavanone (1)

First Public Date

2026 (23)
2024 (20)
2025 (12)
2014 (10)
2020 (8)
2022 (7)
2021 (7)
2018 (6)
2016 (6)
2023 (5)
2019 (4)
2015 (1)

Study status

Recruiting (15)
Completed (14)
Not provided (9)
Terminated (8)
Active, not recruiting (4)
Ongoing (3)
Withdrawn (1)
Not yet recruiting (1)

Study type

Transcription profiling by array (237)
Interventional (46)
RNA-seq of coding RNA (42)
RNA-seq of non coding RNA (15)
Unknown experiment type (9)
Comparative genomic hybridization by array (8)
Observational (7)
Methylation profiling by array (6)
Transcription profiling by SAGE (5)
ChIP-seq (4)
Proteomic profiling by array (4)
Transcription profiling by tiling array (3)
Other (3)
Cell line - Single-cell sequencing (1)
Human - One-color microarray (1)
Proteomic profiling by mass spectrometer (1)
RNAi profiling by array (1)
Methylation profiling by high throughput sequencing (1)
Other (1)
Observational patient registry (1)

Release Date

2022 (149)
2021 (148)
2015 (123)
2020 (113)
2025 (105)
2019 (104)
2023 (100)
2017 (86)
2016 (85)
2014 (84)
2024 (82)
2012 (72)
2018 (72)
2013 (69)
2010 (62)
2011 (50)
2009 (23)
2008 (18)
2026 (15)
2007 (8)
2006 (1)
2005 (1)
2004 (1)
2003 (1)

Lab affiliation

Department of Molecular Cell Biology, Weizmann institute of Science, Israel (5)
Professor Institutt for klinisk og molekylær medisin Norges teknisk-naturvitenskapelige universitet Erling Skjalgssons g 1, Laboratoriesenteret * 231.05.036 Trondheim 7030 Norway (2)
Centre de recherche du Centre Hospitalier Universitaire (CHU) de Quebec-Université Laval, Québec, QC, Canada Centre de recherche sur le cancer de l’Université Laval, Québec, QC, Canada PROTEO-Quebec Network for Research on Protein Function, Engineering, and Applications, Québec, QC, Canada Department of Molecular Biology, Medical Biochemistry and Pathology, Université Laval, Québec, QC, Canada (1)
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany. (1)
Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel (1)
Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Canada (1)
Dipartimento di Scienze e Tecnologie Ambientali Biologiche e Farmaceutiche Università degli Studi della Campania“Luigi Vanvitelli” (1)
IRIC-Université de Montréal (1)
Institute of Chemistry, Academia Sinica, Taiwan (1)
McKusick-Nathans Institute of Genetic Medicine, Department of Biological Chemistry, Oncology and Pathology, Johns Hopkins University School of Medicine, Baltimore 21205, Maryland, USA (1)
Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany (1)
School of Biological Science, Associate Professor Valerie Lin Chun Ling's research lab, Nanyang Technological University (SBS, NTU), Singapore (1)
University of Oxford Discovery Proteomics (DisPro) (1)

Location

United States (12)
Italy (11)
Spain (10)
France (9)
Belgium (8)
Germany (8)
Australia (5)
United Kingdom (5)
Japan (5)
Netherlands (5)
China (3)
Saudi Arabia (2)
India (2)
Poland (2)
Russia (2)
South Korea (2)
Czechia (2)
Canada (2)
Cyprus (1)
Hong Kong (1)
New Zealand (1)
Asia except Japan (1)
Europe (1)
North America (1)
Turkey (1)
Greece (1)
Israel (1)
Switzerland (1)

Keyword

Panitumumab (15)
Cetuximab (9)
Irinotecan (8)
Fluorouracil (7)
Leucovorin (5)
Levoleucovorin (5)
Folic Acid (4)
Antibodies (4)
Oxaliplatin (4)
Antibodies, Monoclonal (3)
Bevacizumab (3)
Anti-EGFR (2)
Oxaliplatino (2)
MSI (2)
Colorectal (2)
Antineoplastic Agents, Immunological (2)
Immunoglobulins (2)
Cetuximab rechallenge (1)
Hidrocloruro de irinotecán trihidrato (1)
Vectibix 20 mg/mL concentrate for solution for infusion (1)
Erbitux 5 mg/mL solution for infusion (1)
Avastin 25 mg/ml concentrate for solution for infusion (1)
Sunitinib (1)
R0 R1 liver resection (1)
Resectability of liver (1)
Liver expert panel (1)
Panitumumab (1)
Rechallenge (1)
RAS mutations (1)
Cetuximab (1)

Previous page
1 / 187
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 187
Next page

Sort by:

Relevance

Page size

Resistance to anti-EGFR therapy in colorectal cancer

Monoclonal antibodies targeting the Epidermal Growth Factor Receptor (EGFR), such as cetuximab and panitumumab, have evolved to important therapeutic options in metastatic colorectal cancer (CRC). However, almost all patients with clinical response to anti-EGFR therapies show disease progression wit...

EGAS00001000582 | EGA

ena-DATASET-MUG-29-10-2013-10:52:10:827-14 - samples

In this study we performed ultra deep sequencing of genes associated with anti-EGFR resistance, such as KRAS, BRAF, PIK3CA, and EGFR in 17 plasma-DNA samples from a total of 10 patients treated with anti-EGFR therapy.

EGAD00001000688 | EGA

ena-DATASET-MUG-26-02-2014-10:25:52:632-26 - samples

In this study we performed whole genome sequencing of plasma DNA (plasma-Seq) of 19 plasma-DNA samples from a total of 10 patients treated with anti-EGFR therapy. We demonstrated that development of resistance to anti-EGFR therapies is frequently associated with focal amplifications of KRAS, MET, an...

EGAD00001000748 | EGA

Monitoring of RAS/EGFR mutations in circulating tumor DNA to guide anti-EGFR therapy in mCRC patients: The CHRONOS trial

PRJEB49484 | ENA

Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer

AREG/EREG and outcomes from anti-EGFR therapy in mCRC

PRJEB63103 | ENA

Adverse Events of anti-EGFR Therapy are Triggered by Hair Eruption and Commensal Skin Microbiota

PRJNA489001 | ENA

Evaluation of gene expression changes upon acquired resistance to anti-EGFR targeted therapy in head and neck squamous cell carcinoma

PRJNA1327762 | ENA

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple Negative Breast Cancer

Abstract Background. Epidermal growth factor receptor (EGFR) is a targetable molecule in basal-like breast cancer, which comprises most “triple negative” breast cancer (TNBC), the only breast cancer subtype without established targeted therapy. Methods. In this randomized phase II trial, metastatic ...

ORGANISM(S): Homo sapiens

2012-07-13 | E-GEOD-23428 | biostudies-arrayexpress

Gene expression changes associated with acquired resistance to anti-EGFR therapy (cetuximab) in colorectal cancer cells

PRJNA1093402 | ENA

Genetic Study of anti-EGFR Antibody Therapy Response in Colorectal Carcinoma

PRJNA498496 | ENA

Previous page
1 / 187
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 187
Next page

Sort by:

Relevance

Page size

1862 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets